Specific contract for the supply of the medicinal product ROACTEMRA 200MG/10ML IV VIAL (active substance tocilizumab) via the Dynamic Acquisition System SDA ARIA_2025_045 for a duration of 12 months

different companies won its awards

30

of the awards went to the three most frequent winners

18%

of its calls state an estimated value

87%

Based on 40 awards with a named winner over the last 3 years. Counted by award, not by value, because lot and framework amounts are not comparable. Concentrated means the three most frequent winners took 65% or more of the awards; many suppliers, under 35% with at least ten different winners.

Italy · Medical equipment & pharmaceuticals

different companies won awards here

1,670

of the awards went to the three most frequent winners

3%

winners of the last 12 months were new here

1,375 of 1,439

buyers awarded contracts here

389

Based on 2,607 awards with a named winner over the last 3 years. Counted by award, not by value, because lot and framework amounts are not comparable. Concentrated means the three most frequent winners took 65% or more of the awards; many suppliers, under 35% with at least ten different winners. New: no award from the same buyer or market in the two years before.

Competition

tenders per lot on average (open and restricted procedures)

1.9

of those lots received a single tender

38%

of the awards went to companies based in another country

1%

of the tenders came from another country

1%

As the official award notices state them, over the last 3 years. Tenders per lot count open and restricted procedures only: in a negotiated procedure or a direct award a single tender is the procedure itself. The country is the one the notice gives for the winner.